NCT06507956Recruiting
Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
Source: ClinicalTrials.gov · Last updated 21 Nov 2025
Brief summary (registry, in English)
Cystic fibrosis is a multisystem genetic disease whose severity, linked to the nature of the mutation in the gene carried, is linked to respiratory impairment, which determines the vital prognosis. Considerable progress has been made in the management of this disease, amplified in recent years by the arrival of CFTR (cystic fibrosis transmembrane conductance regulator) modulator drugs, and in particular the triple treatment combination of elexacaftor-tezacaftor-ivacaftor (ETI). This modulator therapy improves clinical condition, particularly respiratory, and transforms quality of life and prognosis for some patients. Faced with this clinical improvement, practices and care paths are adapting. Professionals will have to cope with the emergence of new clinical conditions linked to the ageing of this at-risk population and the functional decline due to a sedentary lifestyle and age. The working hypothesis is that a better understanding of the physical activity and sedentary lifestyle profiles of the adult population with cystic fibrosis, and in particular the characterization of the profile of inactive and high sedentary patients under ETI, will enable us to identify and target patients whose lifestyle habits reflect a greater health risk, and for whom care by rehabilitators and adapted physical activity (APA) teachers and personalized advice could be put in place. The aim of this study is to characterize the physical activity and sedentary profile of adults with cystic fibrosis. ACTIVMUCO is an observational, cross-sectional, single-center study. A subgroup of adults with high sedentary and inactive under ETI will be studied more specifically by actimetry (prospective follow-up) and interview.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 270 (estimated)
- First submitted
- 10 Jul 2024
- Start date
- 17 Sept 2024
- Primary completion date
- 3 Sept 2026
- Lead sponsor
- Hospices Civils de Lyon
- Diseases
- Cystic fibrosis
- NCT number
- NCT06507956
What you commit to
- Study type: Observational
- Planned participants: 270
- From 17 Sept 2024 to the primary completion date, 3 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Persons under psychiatric care
Other
- People who, due to the presence of co-morbidities, do not have motor and cognitive skills compatible with independent walking or orthostatic physical activity.
- People whose clinical situation contraindicates the practice of adapted physical activity
- Pregnant women
- People who do not have the intellectual or linguistic capacity to understand the questionnaires
- Persons deprived of their liberty by judicial or administrative decision
- Persons admitted to a health or social establishment for purposes other than research
- Adults under legal protection (guardianship, curatorship).
- Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
Who the study is looking for
- Patients (male or female) of legal age,
- Patients with cystic fibrosis (CF) regularly followed at Hôpital Lyon Sud's cystic fibrosis center, who volunteered to take part in the study.
Age in the registry: 18 years to 65 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Lyon Sud Coordinator of this site? Confirm its status | Pierre-Bénite | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.